Premium – Page 2 – Endpoints News

SUBSCRIBE

The BCMA frenzy: Tracking the 37 drugs around the world racing to overtake bluebird bio and Celgene

6 months ago

Top 5 Chinese players: What does Everest's landmark deal with Immunomedics say about the flurry of in-licensing to China?

6 months ago

Going gangbusters: The top 20 biotech platform deals by upfront cash

7 months ago

Another player in the gene therapy field is gunning for the Duchenne MD crown — and here’s what they're betting on

7 months ago

The top 20 preclinical biotech deals ranked by cash upfront reveals 3 big players — and some major league stinkers

7 months ago

Top 20 cancer drug deals: AstraZeneca just changed the global landscape for dealmaking in oncology

7 months ago

The top 10 Alzheimer's deals tell us a lot about a big change of direction for a disaster-prone field

7 months ago

Team building. Pipeline revamp. Forward thrust. What does a decade of deals at Gilead tell us about Daniel O’Day’s first M&A moves?

8 months ago

After a slate of small, tack-on acquisitions, is Merck ready to pull the trigger on a big M&A deal?

8 months ago

By the numbers: Top M&A deals, VC investments and pacts point to a growing hunger for gene therapy deals

8 months ago

The $100M biotech club: Who's in, and what’s it take to join the top-performing group of biopharmas?

9 months ago

The high rollers: The top 20 blockbuster biopharma deals of the past decade

9 months ago

Top 20 biotech deals: 2019 dealmaking gets off to a roaring start, building on a record amount for '18

9 months ago

AstraZeneca CEO Soriot is overseeing a top exec team overhaul in move to integrate MedImmune in a sweeping restructuring

9 months ago

Path to the top: What kind of experience does it take to get tapped for the helm of a biotech?

9 months ago

By the numbers for 2018: The top 100 venture players in biotech — and who's been paying the piper in cancer R&D?

9 months ago

Scoop: GSK’s venture team at SR One in talks to spin off from its big pharma founder, now under new R&D management

9 months ago

Celgene's top 20 upfront hits: Just how generous was Celgene in dealmaking? Let's review the records

10 months ago

So what did we learn from JPMorgan week? Buckle up, it’s going to be a bumpy ride

10 months ago

‘It’s us against the world’: And George Yancopoulos wants you to know they are beating the world — big time

10 months ago

The 2018 breakdown on a chart-topping set of new drug approvals — and the 5 big things we learned from it

10 months ago

The Great Pharma Brexit? An Endpoints News snap poll finds most life sciences insiders predicting a debacle for the industry

11 months ago

Winners and losers at #ESMO18

Last year

Exclusive: At Hal Barron’s R&D group at GSK, consensus is out, leaders are in and watch out for an ‘intense drive’ to spur the late-stage pipeline

Last year

First page Previous page 123 4 Next page Last page